Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apyx Medical CorpAPYX · Entity 6609 | Director · Chief Executive Officer | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apyx Medical Corp
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Option to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.65 · Expires 2036-06-11 | Direct | 213,948 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 213,948 · Balance 213,948 F1: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 23:00 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 213,948 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001493152-26-028770 · ownership.xml · derivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,948 Underlying: Common Stock · 213,948 shares Expires 2036-06-11 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:31 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 193,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001641172-25-011474 · ownership.xml · derivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,000 Underlying: Common Stock · 193,000 shares Expires 2035-05-15 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:07 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 50,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001493152-25-002763 · ownership.xml · derivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-15 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty-six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 21:05 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 243,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001493152-24-002060 · ownership.xml · derivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 243,000 shares Expires 2034-01-10 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:12 UTC | Apyx Medical Corp APYX · Entity 6609 | PurchaseCommon Stock | 50,000 | $1.57 | $78,500.00 |
DisclosureSEC source: 0001493152-23-041501 · ownership.xml · nonDerivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 F1 · price: This transaction was executed in multiple trades at a prices ranging from $1.56 to $1.57. The reported price in Column 4 is a weighted average price, rounded to the nearest hundredth. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 21:16 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 243,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000719135-23-000003 · wf-form4_167364454886580.xml · derivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,000 Underlying: Common Stock · 243,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 20:51 UTC | Apyx Medical Corp APYX · Entity 6609 | PurchaseCommon Stock | 9,750 | $5.97 | $58,207.50 |
DisclosureSEC source: 0000719135-22-000084 · wf-form4_166197908352652.xml · nonDerivative · entry 2 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F2 · price: This transaction was executed in multiple trades at prices ranging from $5.90 to $5.99. The reported price in Column 4 is a weighted average price, rounded to the nearest hundredth. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 20:51 UTC | Apyx Medical Corp APYX · Entity 6609 | PurchaseCommon Stock | 2,000 | $5.93 | $11,860.00 |
DisclosureSEC source: 0000719135-22-000084 · wf-form4_166197908352652.xml · nonDerivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,250 F1 · price: This transaction was executed in multiple trades at prices ranging from $5.92 to $5.93. The reported price in Column 4 is a weighted average price, rounded to the nearest hundredth. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 19, 2022 Filed Feb 1, 2022 00:11 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 243,000 | $0.00 Strike: $10.96 | $0.00 |
DisclosureSEC source: 0000719135-22-000008 · wf-form4_164367424996384.xml · derivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,000 Underlying: Common Stock · 243,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| January 29, 2021 Filed Feb 9, 2021 16:35 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantCommon Stock · Derivative | 121,500 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0000719135-21-000008 · wf-form4_161288853061139.xml · derivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,500 Underlying: Common Stock · 121,500 shares Expires 2031-01-29 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| May 13, 2020 Filed May 14, 2020 17:27 UTC | Apyx Medical Corp APYX · Entity 6609 | PurchaseCommon Stock | 28,250 | $3.30 | $93,196.75 |
DisclosureSEC source: 0000719135-20-000045 · wf-form4_158947721868646.xml · nonDerivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,250 F1 · price: Average price of shares purchased on the open market on May 13, 2020, ranging from $3.06 to $3.33 per share. Read SEC document |
| January 15, 2020 Filed Jan 22, 2020 22:17 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 243,000 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0000719135-20-000009 · wf-form4_157973140374028.xml · derivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,000 Underlying: Common Stock · 243,000 shares Expires 2030-01-15 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| January 09, 2019 Filed Feb 12, 2019 00:17 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 236,000 | $0.00 Strike: $7.91 | $0.00 |
DisclosureSEC source: 0000719135-19-000014 · wf-form4_154993062663073.xml · derivative · entry 1 Goodwin Charles D. II · CIK 0001726988 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,000 Underlying: Common Stock · 236,000 shares Expires 2029-01-09 F1 · derivative.exercise_price: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.